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Summary. We report a case of Sezary syndrome with two
abnormal CD4+ T-cell populations detected in the peripheral
blood by flow cytometry immunophenotyping and DNA cell
content, suggesting a biclonal T-cell lymphoproliferative
disorder. Despite these findings, molecular analysis of the
T-cell receptor genes was consistent with a monoclonal
T-cell proliferation, supporting the existence of intraclonal
diversity rather than a true biclonal disease. The patient
achieved a transient response with 2-deoxycoformycin,
with a selective decrease of the larger/hyperploid T-cell
population; later on, an increased representation of this
T-cell population was observed concomitantly with clinical
relapse.
Keywords: Sezary syndrome, biclonal, intraclonal diversity,
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Sezary syndrome (SS) is a cutaneous CD4+ T-cell non-
Hodgkin’s lymphoma that manifests with generalized
erythroderma and blood circulating cerebriform cells (Siegel
et al, 2000). Treatment includes photopheresis, total skin
electron beam therapy, single-agent and combined chemo-
therapy and immunotherapy. Recent studies suggest that
pentostatin (2-deoxycoformycin, 2-DCF), a potent inhibitor
of the adenosine deaminase with activity in a range of
lymphoid malignancies, is an effective single-agent therapy
for SS (Dearden et al, 2000).
In contrast to B-cell disorders, in which clonality can be
demonstrated through the finding of immunoglobulin light
chain restriction, assessment of T-cell clonality by immu-
nophenotyping still remains complex and currently depends
on either the demonstration of an aberrant immunopheno-
type and/or the study of the T-cell receptor (TCR) b-chain
variable region (Vb) repertoire using a large panel of
monoclonal antibodies; in such cases, T-cell clonality is
considered when a single TCR-Vb domain is expressed
(Lima et al, 2001a). However, demonstration of T-cell
clonality formally needs molecular analysis of the configur-
ation of the TCR genes.
Here we report a patient with SS with a monoclonal
proliferation of CD4+ T cells in the peripheral blood in
whom intraclonal heterogeneity was demonstrated by flow
cytometry immunophenotyping and DNA cell content;
these two distinct CD4+ T-cell populations responded
differently to therapy with 2-DCF.
To the best of our knowledge this is the first report
describing a cutaneous T-cell lymphoma in which intra-
clonal diversity correlated with clinical manifestations and
response to therapy.
CASE REPORT
A 79-year-old man was diagnosed with SS in 1998 and
subsequently treated with Interferon a2b (3 · 106 U, sub-
cutaneously, three times per week) plus photochemotherapy
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(Psoralen and ultra-violet A, PUVA) without an objective
response. He was first observed in the Haematology Depart-
ment of the Hospital S. Joa˜o (Porto, Portugal) in March 1999
with generalized erythroderma and pruritus. Blood counts
were as follows: haemoglobin 12Æ3 g/dl, platelets
163 · 109/l and white blood cell count (WBC)
11Æ8 · 109/l (lymphocytes 4Æ3 · 109/l). The peripheral
blood film showed a mixture of small- and large-sized
lymphocytes with a cerebriform nucleus and the skin biopsy
revealed dermal infiltration by atypical lymphoid cells with
epidermotropism. Flow cytometry analysis of peripheral
blood leucocytes performed in whole blood by a stain-
and-lyse direct immunofluorescence technique with a
four-colour panel of monoclonal antibodies revealed two
abnormal CD4+ T-cell populations co-existing with a small
population of normal residual CD4+ T cells (Fig 1). The two
abnormal CD4+ T-cell populations had different light scatter
properties, one with a forward scatter (FSC) and a side
scatter (SSC) similar to normal CD4+ T cells (small Sezary
cells) and the other being larger and more complex (large
Sezary cells). In addition, they also differed one from each
other on the pattern of expression of CD2, CD3/TCRab, CD4,
CD5, CD7, CD11a and HLA-DR. Small Sezary cells were
CD7+bright and expressed virtually no CD2, whereas large
Sezary cells were CD2+bright and showed dim and heteroge-
neous reactivity for CD7. Although with different intensities,
both cell populations expressed CD5 brightly and the TCRab,
CD3 and CD4 antigens dimly in comparison to normal CD4+
T cells. In addition, small abnormal CD4+ T cells were
CD11a+dim, CD25– and HLA-DR– and large abnormal CD4+
T-cells were CD11a+bright, HLA-DR–/+dim and CD25–/+dim.
Both T-cell populations were CD28 and CD45RO positive
while negative for other T-/natural killer (NK)-cell markers
tested (CD8, CD11b, CD11c, CD16, CD38, CD45RA, CD56,
CD62L, CD57, CD94, CD122, CD158a, CD161, NKB1).
TCR-Vb repertoire studies using a panel of monoclonal
antibodies that identify 23 different TCR-Vb families and
covers around 60 ± 4% of the TCR-Vb repertoire of CD4+ T
cells present in the normal adult peripheral blood (Lima et al,
2001a) showed a dilution pattern, with 93% of CD4+ T cells
remaining unidentified with the panel of anti-TCR-Vb
monoclonal antibodies used in the study. Flow cytometry
DNA cell content studies showed that small abnormal
CD4+ Sezary cells were diploid (DNA index, 0Æ98)
whereas large aberrant ones were hyperploid (DNA index,
1Æ90); in addition, the small Sezary cells had a higher
percentage of cells in S phase (1Æ9% vs 0Æ7%) whereas large
Sezary cells had a higher mitotic index (% G2/M phase
cells of 5Æ3% versus 0Æ6%) (Table I). Southern blot (SB)
analysis of the DNA extracted from blood mononuclear
cells treated with the EcoR1 and HindIII restriction
enzymes and hybridized with 32P-labelled probes for the
constant region of the TCRb gene (cb) showed a TCR
rearrangement pattern compatible with a monoclonal T-cell
proliferation. At diagnosis, the bone marrow aspirate had
18% lymphoid cells, of which 97% were CD4+ T cells (54%
large abnormal; 45% small abnormal and 1% small normal
residual CD4+ T cells).
The patient was treated with 2-DCF (4 mg/m2, intraven-
ously, once a month, for 5 months) with significant
improvement of the skin lesions and marked reduction in
the blood lymphocytosis to 0Æ779 · 109/l in April 2000
(Fig 2). Large CD4+ Sezary cells almost disappeared whereas
small CD4+ Sezary cells persisted in the blood (Fig 2). He
remained stable until July 2000, when the disease recurred
with erythroderma, lymphadenopathy, increasing lympho-
cytosis (WBC 9Æ9 · 109/l; lymphocytes 4Æ6 · 109/l) and
reappearance of the large CD4+ Sezary cells in blood (Fig 2).
He was restarted on 2-DCF (4 mg/m2, intravenous, once a
month) plus prednisolone (100 mg, per os, 5 d, once a
month) with clinical and haematological response but died
from lung infection in January 2001.
Fig 1. Dot plots illustrating the main phenotypic features of both small (green dots) and large (red dots) aberrant CD4+/CD3+/TCRab+ T cells, in
comparison to normal residual T lymphocytes (black dots).
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DISCUSSION
In recent years an increasing number of biclonal lympho-
proliferative disorders (LPD) have been described due to a
more accurate approach to the diagnosis. Most of the
documented cases were referred to as biclonal B-cell LPD
and a few as concomitant B- and T-cell LPD (Moss &
Gillespie, 1997; Lima et al, 2001b), the latter including
patients with cutaneous T-cell lymphoma co-existing with a
B-cell leukaemia (Alves et al, 1998; Paolini et al, 2000).
Cases of biclonal T-cell LPD are quite rare, only three well-
documented reports have been described in the literature
during the last decade (UltraMed, including MedLine,
1990–2001) (Richards et al, 1994; Kondo et al, 1995;
Shibata et al, 1995). Two of these cases were biclonal
human T-cell leukaemia virus type I (HTLV1)-positive adult
T-cell leukaemia/lymphoma, in which two different T-cell
clones were identified by immunophenotyping, TCR gene
rearrangement studies and analysis of the integration
pattern of HTLV-I proviral DNA (Kondo et al, 1995; Shibata
et al, 1995); the remaining case was a patient with large
granular lymphocytic leukaemia that proved to be biclonal
by immunophenotyping and demonstration of the simulta-
neous presence of distinct TCR gene rearrangements (Rich-
ards et al, 1994). A case of a patient with SS in whom
biclonality was considered highly probable based on the
identification of two different abnormal T-cell populations
by immunophenotyping has also been reported, although
the different clonal origin was not demonstrated (Dereure
et al, 1994).
In the present case, two abnormal CD4+ T-cell popula-
tions were detected by flow cytometry immunophenotyping
and DNA cell content studies, raising the question of
whether these two T-cell populations were the result of
Fig 2. Blood cell counts and immunopheno-
typic enumeration of peripheral blood
lymphocytes at diagnosis and at different
times during follow-up after starting treat-
ment with 2-DCF. The WBC counts (– –) and
the lymphocyte counts (–d–) counts are
shown in the upper panel. The lower panel
shows the relative representation of large
abnormal CD4+ Sezary T cells (red bars), small
abnormal CD4+ Sezary T cells (green bars)
and small normal residual CD4+ plus CD8+ T
lymphocytes (black bars), as the percentage of
total peripheral blood T cells. Dot plots in the
top of the upper panel represent the SSC/FSC
distribution of peripheral blood cells as well as
the percentage of each cell population among
total white blood cells from the sample (for
key, see Fig 1).
Table I. DNA content and cell cycle distribution of peripheral blood T cells at diagnosis.
Ploidy DNA index % G0/G1 % S % G2M
Small abnormal CD4+ T cells Diploid 0Æ98 97Æ5 1Æ9 0Æ6
Large abnormal CD4+ T cells Hyperploid 1Æ90 94Æ0 0Æ7 5Æ3
Normal residual T cells Diploid 1Æ00 98Æ2 1Æ0 0Æ8
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intraclonal diversity associated with chromosome instability
or rather represent a true biclonal disease. Unfortunately,
flow cytometry TCR-Vb studies were of limited value in
clarifying this point as the panel of anti-TCR-Vb monoclonal
antibodies used did not identify the TCR-Vb family expressed
in either of the two phenotypically aberrant T-cell popula-
tions. Molecular studies revealed a monoclonal TCRb chain
gene rearrangement pattern, strongly favouring the hypo-
thesis of intraclonal heterogeneity rather than the existence
of a biclonal T-cell LPD. Although it could be argued that SB
has a relatively low sensitivity and that a more sensitive
polymerase chain reaction (PCR)-based technique should be
used to clarify this point, the possibility of missing one of the
clones in SB analysis is very unlikely as each of the two
abnormal CD4+ T-cell populations represented nearly half of
the total circulating mononuclear cells at the time when the
molecular studies were performed, a value which is clearly
above the cut-off level of 5–10%, usually considered as the
sensitivity limit for this technique.
Intraclonal diversity has been demonstrated in both
B- and T-cell LPD. Histological transformation of B-cell
lymphomas is frequently associated with clonal heterogen-
eity due to ongoing somatic mutations and acquisition of
new chromosomal abnormalities (Whang-Peng et al,
1995; Matolcsy et al, 1999; Szereday et al, 2000). The
occurrence of large cell transformation has been docu-
mented in patients with mycosis fungoides/SS (Diaman-
didou et al, 1998; Li et al, 1998; So et al, 2000) and, as in
this patient, at least one case has been previously reported
in which large cells proved to be hyperploid by conven-
tional karyotyping and DNA cell content staining (So et al,
2000).
In the case described here, flow cytometry proved to be of
great help in detecting intraclonal heterogeneity, and in
quantifying and characterizing the two abnormal T-cell
populations as well as in monitoring during and after
therapy. Interestingly 2-DCF seemed to act preferentially in
one of the lymphoma T-cell populations, as large DNA
hyperploid CD4+ Sezary T cells selectively decreased after
treatment. Moreover, the clinical manifestations correlated
to the presence of such a clone, as reappearance of
erythroderma occurred simultaneously with an increase in
the large DNA hyperploid CD4+ Sezary cells in the periph-
eral blood.
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